The cost of newly diagnosed breast cancer in Lithuania, 2011

Ivanaūskienė, Rugile; Domeikienė, Auksė; Kregždytė, Rima; Milašauskienė, Žemyna; Padaiga, Žilvinas

doi:10.1016/j.medici.2015.01.002

Cited by 7 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with other studies [24][25][26][27], the medication costs accounted for the major portion of total costs, due to the high price of new chemotherapeutic agents. On the other hand, the price of services in Jordan and other developing countries was relatively low compared with developed countries.…”

Section: Discussionsupporting

confidence: 88%

“…This is similar to the findings of Barron's et al [30], where laboratory cost stands as the second highest cost driver after hospitalization. However, in other studies, laboratory test costs were minimal compared with other healthcare resources spent [25,26]. Hospitalization cost (i.e., hospital stay cost) was found to be the third highest cost driver in this study, representing 6.7% of the total direct medical cost.…”

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Alefan

Saadeh

Yaghan

2020

Breast Cancer Manag.

View full text Add to dashboard Cite

Aim: To analyze the direct medical costs of breast cancer (BC) patients in the north of Jordan. Patients: A cohort of BC patients treated during 2015 at King Abdullah University Hospital. Methods: A retrospective analysis of 119 patients, where all records including age, sex, treatment processes and costs were extracted from the patients’ profiles and examined. Results: The mean age of patients was 50.8 (±10.2) years. The total sample cost was Jordanian dinar 1,393,325 (US$1,963,560). The mean cost per patient from stage I to IV was Jordanian dinar 6696, 9183, 11,970 and 15,073, respectively. Medications were the most expensive resource used. Stage IV had the highest cost and largest number of patients. Conclusion: Direct medical costs associated with BC are considerable. Three-quarters of the cost were devoted to medications.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 50%

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Alefan

Saadeh

Yaghan

2020

Breast Cancer Manag.

View full text Add to dashboard Cite

show abstract

“…Our study also showed that hospitalization costs, albeit consistently lower than medication costs, increased as the disease progressed. This finding is, however, inconsistent with other studies that reported higher hospitalization costs for breast cancer patients; this may be ascribed to differences in the healthcare systems, patient populations, and treatment protocols evaluated [ 35 , 36 ]. Assessing the impact of decreased hospitalization costs on overall cost and quality of life, compared to that reported in other countries, would be an interesting topic for future investigation.…”

Section: Discussioncontrasting

confidence: 92%

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

et al. 2021

View full text Add to dashboard Cite

Globally, breast cancer management is associated with a heavy economic burden, but its impact in Saudi Arabia has not been fully quantified. The aim of this study was to estimate the economic burden of breast cancer management at various disease stages, in Saudi Arabia, from a payer perspective. We conducted a retrospective, multicenter cost of illness study in two governmental healthcare centers from January to December 2018, using the data of 300 patients at different breast cancer stages. A micro-costing, bottom-up method was used, and descriptive and inferential statistics were analyzed. The total estimated cost for treating breast cancer during the study period was $13.345 million USD, with the average cost per patient ranging from $14,249 USD in stage I to $81,489 USD in stage IV (p < 0.001). Medication cost was the main driver of total healthcare spending, followed by hospitalization and diagnostic tests. The cost of targeted therapy drugs represented 67% of the total medication costs, mostly driven by trastuzumab-based regimens. The economic burden of breast cancer management in Saudi Arabia is substantial and increases significantly with disease advancement. Early detection screening programs, evaluating the value of highly expensive interventions, and considering biosimilars, may contribute toward cost savings.

show abstract

“…The economic aspects of BC have been subject to growing awareness in health services research and most studies focused on costs of the disease. The studies estimating direct costs conducted in the United States [ 7 – 11 ], Germany [ 12 ], Poland [ 6 , 13 ] and Lithuania [ 14 ] provide evidence on the magnitude of costs associated with BC treatment while the research focusing on indirect costs estimate productivity losses in Spain [ 15 ] and Lithuania [ 16 ]. Recently, there has been a growing interest in research combining direct and indirect costs within the cost-of-illness framework [ 17 ] as examples from Iran [ 18 ], Korea [ 19 ], Flanders [ 20 ], Sweden [ 21 ], Japan [ 22 ] and California [ 23 ] show.…”

Section: Introductionmentioning

confidence: 99%

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014

Łyszczarz

Nojszewska

2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundApart from the health and social burden of the disease, breast cancer (BC) has important economic implications for the sick, health system and whole economy. There has been a growing interest in the economic aspects of breast cancer and analyses of the disease costs seem to be the most explored topic. However, the results from these studies are hardly comparable. With this study we aim to contribute to the field by providing estimates of productivity losses and public finance burden attributable to BC in Poland.MethodsWe used retrospective prevalence-based top-down approach to estimate the productivity losses (indirect costs) of BC in Poland in the period 2010–2014. Human capital method (HCM) and societal perspective were used to estimate the costs of: absenteeism of the sick and caregivers, presenteeism of the sick and caregivers, disability, and premature mortality. We also used figures illustrating public finance burden attributable to the disease. Deterministic sensitivity analysis was performed to assess the stability of the estimates. A variety of data sources were used with the social insurance system and Polish National Cancer Registry being the most important ones.ResultsProductivity losses associated with BC in Poland were €583.7 million in 2010 and they increased to €699.7 million in 2014. Throughout the period these costs accounted for 0.162–0.171% of GDP, an equivalent of 62,531–65,816 per capita GDP. Losses attributable to disability and premature mortality proved to be the major cost drivers with 27.6%–30.6% and 22.0%–24.6% of the total costs respectively. The costs due to caregivers’ presenteeism were negligible (0.1% of total costs). Public finance expenditure for social insurance benefits to BC sufferers ranged from €50.2 million (2010) to €56.6 million (2014), an equivalent of 0.72–0.79% of expenditures for all diseases. Potential losses in public finance revenues accounted for €173.9 million in 2010 and €211.0 million in 2014. Sensitivity analysis showed that the results were robust to changes in the model parameters.ConclusionsThe productivity losses attributable to BC in Poland were a sizable burden for the society. They contributed both to decreased economy output and to public finance deficit.

show abstract

The cost of newly diagnosed breast cancer in Lithuania, 2011

Abstract: The direct BC medical cost estimates provided by this analysis can be used to determine priorities for the future research on BC treatment interventions.

Cited by 7 publications

References 11 publications

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014

Contact Info

Product

Resources

About